|
| |
amgen chemocentryx Pages on BioPortfolio:
BioPortfolio - ChemoCentryx, Inc.
24 Nov 2008 ... ChemoCentryx, Inc. - Entry on Bioportfolio's Biocorporate Database. ... developed by ChemoCentryx's partner, Amgen-SF (formerly Tularik). ...
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
BioPortfolio - ChemoCentryx, Inc. - Profile
disorders and CXCR3 receptor antagonists are being developed by ChemoCentryx's partner, Amgen-SF. (formerly Tularik). BioNews Results for ChemoCentryx, Inc.
...
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
BioPortfolio - Biocorporate Search Inflammation1
Over the past quarter century, Amgen has pioneered the methods by which human ... ChemoCentryx is a privately held biopharma company specializing in the ...
http://www.bioportfolio.com/biocorporate/Inflammation-compan...
|
BioPortfolio - CXCR3
Amgen Inc. Drug Metab Dispos. 2008 Dec 16. ... ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available medicines for
...
http://www.bioportfolio.com/indepth/CXCR3.html...
|
BioPortfolio - arzeda
BioPortfolio - arzeda genie scientific | novasecta | amgen chemocentryx ... http ://www.bioportfolio.com/search/Oulu_City_Hall.html. ...
http://www.bioportfolio.com/search/arzeda.html...
|
BioPortfolio - ABGENIX BIOPHARMA CALIFORNIA
BioPortfolio - amgen chemocentryx. Abgenix Reaches Milestone In Antibody Collaboration With Amgen ... with ChemoCentryx Yields Promising Drug Leads South
...
http://www.bioportfolio.com/search/ABGENIX_BIOPHARMA_CALIFOR...
|
Early Stage and Discovery Deals Strategy Structure and Payment ...
Case study 4.3 – Predix Pharmaceuticals / Amgen Inc............................. ................. 38 ... Case study 4.6 – GlaxoSmithKline / ChemoCentryx. ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_712.html...
|
Metabolic and Inflammatory Disease R&D An Assessment of 5 Highly ...
Amgen Astellas AstraZeneca. Bayer Schering Boehringer Ingelheim ... ChemoCentryx . Chemokine Therapeutics ... Amgen AstraZeneca. Hoffman-La Roche Janssen ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_70.html...
|
Diabetes Drug Pipeline
... Alba Therapeutics; Alize Pharma; Altea Therapeutics; Amgen; Amylin Pharmaceuticals ... Cerenis Therapeutics; Chemocentryx; Chong Kun Dang;
CombinatoRx ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_1161.html...
|
BioPortfolio - the biotechnology, pharmaceutical, life science and ...
... DxS and Amgen enter into Collaboration to Provide a K-RAS Companion ... pharma kinetics laboratories | ChemoCentryx CMV | NewLink Genetics Corp | t ...
http://www.bioportfolio.com/bookshop/Operation/ItemSearch/Se...
|
Results from other life science and pharmaceutical sites:
BioPortfolio - ChemoCentryx, Inc.
24 Nov 2008 ... ChemoCentryx, Inc. - Entry on Bioportfolio's Biocorporate Database. ... developed by ChemoCentryx's partner, Amgen-SF (formerly Tularik). ...
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
Tularik Announces Immune Disorders Initiative
Collaboration with ChemoCentryx Yields Promising Drug Leads ... The drug candidates that have been identified in the Tularik-ChemoCentryx collaboration
...
http://www.amgen.com/pdfs/tularik/TLRK_ChemoCentryx061201.pd...
|
BioPortfolio - ChemoCentryx, Inc. - Profile
disorders and CXCR3 receptor antagonists are being developed by ChemoCentryx's partner, Amgen-SF. (formerly Tularik). BioNews Results for ChemoCentryx, Inc.
...
http://www.bioportfolio.com/biocorporate/20818-ChemoCentryx,...
|
Table 1 : Moving targets: cell migration inhibitors as new anti ...
19 Aug 2008 ... SLE, CXCR3, SM, Amgen, phase 1 completed. C5aR, SM, ChemoCentryx, preclinical. Asthma, CRTh2, SM, Oxagen, phase 2 ...
http://www.nature.com/ni/journal/v9/n9/fig_tab/ni.f.210_T1.h...
|
Amgen - Search Results
30, 2008 Amgen Receives Executive Summary from Independent Cochrane ... with ChemoCentryx Yields Promising Drug Leads South San Francisco, CA ... more > ...
http://www.amgen.com/searchresults.jsp?searchString=collabor...
|
Article : Recent Growth Sets Stage for Q4 2006 Genetic Engineering ...
1 Dec 2006 ... ChemoCentryx received an upfront payment of $63.5 million. In addition, the company ... For several months, Genentech had held off Amgen. ...
http://www.genengnews.com/articles/chitem.aspx?aid=1937&chid...
|
Amgen - Media - Tularik Press Release Archives
March 29, 2004, Amgen to Acquire Tularik for $1.3 Billion .... Immune Disorders Initiative; Collaboration with ChemoCentryx Yields Promising Drug Leads ...
http://www.amgen.com/media/tularik.html...
|
BioPortfolio - Biocorporate Search Inflammation1
Over the past quarter century, Amgen has pioneered the methods by which human ... ChemoCentryx is a privately held biopharma company specializing in the ...
http://www.bioportfolio.com/biocorporate/Inflammation-compan...
|
Tularik Initiates Phase 2 Clinical Trial of T487 in Psoriasis
ChemoCentryx is a private, California-based company dedicated to ... T487, while ChemoCentryx will receive certain payments in connection with the ...
http://www.amgen.com/pdfs/tularik/TLRKT487Ph2_121003.pdf...
|
Nature Clinical Practice Gastroenterology & Hepatology | Conflicts ...
He has been a consultant for Alevan, Amgen, Asphelia, Astra Zeneca, Biogen, Caremark, Chemocentryx, Ferring, GlaxoSmithKline, McNeil PPC, and Novartis. ...
http://www.nature.com/ncpgasthep/journal/v5/n11/full/ncpgast...
|
|
